The safety and efficacy of harvesting peripheral blood hematopoietic stem cells (PBSC) were evaluated in 38 children weighing 20 kg or less, with the smallest patient weighing 7 kg. The patients had a median age of 42 months and included 26 children with acute leukemias or lymphoma and 12 with various solid tumors. A total of 81 aphereses were performed, mostly in the recovery phase of chemotherapy, with or without granulocyte colony-stimulating factor, using a CS-3000 cell separator and regular procedure no. 3. Blood was withdrawn at a mean rate of 30 mL/min (range, 17 t o 46 mL/min) through a temporary radial arterial catheter (20 t o 24 guage) and returned through a larger catheter in a peripheral vein. Morbidity related t o PBSC harvest was low and all aphereses were completed within 3 hours. The volume of blood per kilogram processed for each apheresis ranged from 85 to 615 mL (median, 270 mL). The median number of colony-forming units-granulocyte-macrophage ERIPHERAL BLOOD hematopoietic stem cells (PBSC) can be collected and used in cancer therapy. However, initial trials of autografts with PBSC (PBSCT) have been performed mainly in adult patients, and there have been only a few reports in small children."' We have been testing the clinical value of a PBSCT program for children with various types of cancer and have suggested that at least some groups of children with cancer may benefit from high-dose therapy and PBSCT.6-8 For PBSCT to become a routine medical procedure in pediatric oncology, expertise in the collection of PBSC, which includes the procedure itself, the volume processed, catheters, etc, is essential and must be obtained in large-scale trials. We reviewed our records of 38 children who weighed 20 kg or less at the time they underwent apheresis for the collection of PBSC. Emphasis was placed on evaluating the safety and efficacy of the procedure. The engraftment potential of these collected cells was examined by correlating the number of cells infused, including mononuclear cells (MNC), colony-forming unit-granulocyte-macrophage (CFU-GM), and CD34' cells, to the granulocyte and platelet recovery kinetics after infusion. This information will be extended to other pediatric cancer patients. An additional advantage of PBSC is that multiple collection proce- (CFU-GM) and CD34+ cells collected were, respectively, 34 x 104/kg and 15 x 106/kg per apheresis and 126 x 104/kg and 31 X 106/kg per patient. Thirty-three patients (87%) required only a single apheresis t o collect the minimum requirement of 10 X lo' CFU-GM/kg. including 28 patients (74%) from whom 30 x IO' CFU-GM/kg was obtained in a single apheresis. Twenty-three of the patients subsequently underwent autografts with PBSC. The median number of days required t o achieve an absolute granulocyte count of 0.5 x 10s/L and a platelet count of 50 x 109/L were, respectively, 10 (range, 6 t o 15) and 14 (range, 9 t o 46). The patients remained dependent on platelet transfusion support for a median of 10 days (range, 5 to 35). Thus, harvesting PBSC in very small children with active cancers is effective and safe and does not involve the risk of anesthesia or multiple invasive marrow aspirations.
The safety and efficacy of harvesting peripheral blood hematopoietic stem cells (PBSC) were evaluated in 38 children weighing 20 kg or less, with the smallest patient weighing 7 kg. The patients had a median age of 42 months and included 26 children with acute leukemias or lymphoma and 12 with various solid tumors. A total of 81 aphereses were performed, mostly in the recovery phase of chemotherapy, with or without granulocyte colony-stimulating factor, using a CS-3000 cell separator and regular procedure no. 3. Blood was withdrawn at a mean rate of 30 mL/min (range, 17 t o 46 mL/min) through a temporary radial arterial catheter (20 t o 24 guage) and returned through a larger catheter in a peripheral vein. Morbidity related t o PBSC harvest was low and all aphereses were completed within 3 hours. The volume of blood per kilogram processed for each apheresis ranged from 85 to 615 mL (median, 270 mL). The median number of colony-forming units-granulocyte-macrophage ERIPHERAL BLOOD hematopoietic stem cells (PBSC) can be collected and used in cancer therapy. However, initial trials of autografts with PBSC (PBSCT) have been performed mainly in adult patients, and there have been only a few reports in small children."' We have been testing the clinical value of a PBSCT program for children with various types of cancer and have suggested that at least some groups of children with cancer may benefit from high-dose therapy and PBSCT.6-8 For PBSCT to become a routine medical procedure in pediatric oncology, expertise in the collection of PBSC, which includes the procedure itself, the volume processed, catheters, etc, is essential and must be obtained in large-scale trials. We reviewed our records of 38 children who weighed 20 kg or less at the time they underwent apheresis for the collection of PBSC. Emphasis was placed on evaluating the safety and efficacy of the procedure. The engraftment potential of these collected cells was examined by correlating the number of cells infused, including mononuclear cells (MNC), colony-forming unit-granulocyte-macrophage (CFU-GM), and CD34' cells, to the granulocyte and platelet recovery kinetics after infusion. This information will be extended to other pediatric cancer patients. An additional advantage of PBSC is that multiple collection proce-
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(CFU-GM) and CD34+ cells collected were, respectively, 34 x 104/kg and 15 x 106/kg per apheresis and 126 x 104/kg and 31 X 106/kg per patient. Thirty-three patients (87%) required only a single apheresis t o collect the minimum requirement of 10 X lo' CFU-GM/kg. including 28 patients (74%) from whom 30 x IO' CFU-GM/kg was obtained in a single apheresis. Twenty-three of the patients subsequently underwent autografts with PBSC. The median number of days required t o achieve an absolute granulocyte count of 0.5 x 10s/L and a platelet count of 50 x 109/L were, respectively, 10 (range, 6 t o 15) and 14 (range, 9 t o 46). The patients remained dependent on platelet transfusion support for a median of 10 days (range, 5 to 35). Thus, harvesting PBSC in very small children with active cancers is effective and safe and does not involve the risk of anesthesia or multiple invasive marrow aspirations. 0 1995 by The American Society of Hematology.
dures can be performed without anesthesia or invasive surgery, which may be an important consideration in gene therapy because the target patients could be very small children.
PATIENTS AND METHODS
Patients and chemotherapy. The patient characteristics are summarized in Table 1 . The patients included 38 children (21 boys and 17 girls) who weighed 20 kg or less at the time they underwent apheresis collection of PBSC at the University Hospital of Tokushima between 1987 and 1993. The median age of the patients was 42 months (range, 6 to 100 months) and the median body weight was 14 kg. The patient with the lowest body weight of 7 kg was a 12-month-old infant with stage IV neuroblastoma. The youngest patient was a 6-month-old infant with a body weight of 8 kg. Diagnoses included acute lymphoblastic leukemia (ALL; 16 patients), acute myelogenous leukemia (AML; 8 patients), neuroblastoma (NB; 6 patients), brain tumor (BT; 4 patients), non-Hodgkin's lymphoma (NHL; 2 patients), rhabdomyosarcoma (1 patient), and disseminated retinoblastoma (1 patient). Some of the collection data (duration of chemotherapy before apheresis, total number of apheresis procedures, and total number of mononuclear cells and CFU-GM collected) in some of the patients have been published in a previous study.' In children with advanced NB, PBSC were collected from those less than 2 years old at diagnosis only if the parent had requested that PBSC would be used only if initial therapy with surgical resection and short-term chemotherapy failed to eradicate the tumor. The risks of the procedure were explained in detail and informed consent was obtained from the respective guardians. Chemotherapeutic agents were used for both intensive consolidation and better mobilization of stendprogenitor cells. Patients with leukemias or NHL were treated with cytosine arabinoside (2.0 glm2 twice daily [BID] for 5 days) and those with solid tumors received therapy using drugs including doxorubicin, VP-16, cyclophosphamide, cisplatinum, or carboplatinum, as previously reported? All regimens induced a nadir of the absolute granulocyte count (AGC) less than 0.5 x 1OY/L within 10 days after the completion of therapy. The duration 373 colony-stimulating factor (G-CSF 250 to 300 g/m2/day; Kirin Brewery CO, Tokyo, Japan) alone without chemotherapy was administered for mobilization of PBSC. In the remaining patients, apheresis was performed in the recovery phase of chemotherapy when the leukocyte (>1.5 X 109/L), monocyte (>IO%), and platelet (>l50 X 109/L) counts were increasing rapidly, with or without G-CSF, as previously reported."," We found a wide variation between patients in the timing of harvest and, hence, a rather wide window for collection was used to avoid weekend apheresis. Most of the recently treated patients received G-CSF. In the beginning of the program, because indications for G-CSF were limited mostly to patients with solid tumors, more of them received G-CSF than did those with leukemia. No other growth factors were used. If required, subsequent and consecutive apheresis was performed daily. Details of the PBSC collection procedure have been described e l s e~h e r e .~, '~ Briefly, a continuous-flow cell separator (CS-3OOO; Fenwal Laboratory, Dearfield, IL), operated at regular program no. 3, and a granulocyte chamber were used. In this series of patients, we did not use a mohfied procedure with a small-volume collection chamber (SVCC), as reported by Rosenfeld et al." In all of the patients, the extracorporeal line was primed with 400 mL of leukocyte-depleted red blood cells after regular priming with normal saline. In our institute, all patients who weigh less than 30 kg automatically undergo this optional procedure. Acid-citrate-dextrose was used as an anticoagulant in a ratio of 1:6.7 mL of blood, and calcium gluconate (1 to 2 mL/200 mL of processed blood) was administered continuously during apheresis to prevent hypocalcemia. No other drugs were used and patients were not sedated during the procedure.
In all of the patients, a central line was routinely inserted at the initial diagnosis, but this was not used for withdrawal or return of processed blood during apheresis. Instead, blood was withdrawn through a temporary radial arterial catheter (20 to 24 guage; Terumo CO, Tokyo, Japan) to ensure adequate blood flow. During apheresis, the largest possible catheter, primarily determined by technical ease of insertion, was used, with or without local anesthesia. When patients were to undergo aphereses on a daily basis, the line was not removed and continuous infusion of heparin solution was used to prevent occlusion of the line. At the start of apheresis, blood withdrawal was fixed at 15 mL/min when using a 24-guage catheter and at 20 W m i n with a 22-guage catheter. After processing 50 to 100 mL of blood, this rate was gradually increased to the maximum rate achievable. The rate of blood withdrawal that was maintained for the longest duration per apheresis was considered the "average" rate. Processed blood was returned through an 18-to 22-guage catheter in a peripheral vein in either the antecubital or foot areas. The speed of granulocyte and platelet recovery after PBSCT is primarily determined by the number of infused CFU-GM." Harvest was repeated until more than 10 X lcv' CFU-GMkg was collected or until cell yield decreased and no additional clinical benefits could be achieved with apheresis. Complications related to apheresis were assessed up to 2 weeks postapheresis unless the patient directly underwent the next course of chemotherapy or PBSCT. In the first series of collection, we routinely perform only two consecutive aphereses over a 2-day period and then administer the next course of consolidation therapy. Approximately 4 weeks later, we determine whether a third apheresis is necessary, with the criterion being greater than 10 X lo4 CFU-GMkg. By that time, data from the clonogenic assay are available.
Processing and storage of PBSC. The cells obtained by apheresis in a 2OO-mL collection bag were transferred to four 50-mL tubes and centrifuged at l50g for 15 minutes to remove the plateletrich plasma, which was subsequently reinfused into the patients. The pellet was resuspended in Caz+-and Mgz+-free phosphate buffer at 1 to 2 X lo8 cells/mL. Cells were then fractionated on a discontinuous gradient of 40% and 60% Percoll.'4 Cells recovered in the interface were cryopreserved using either the conventional procedure in a Cryo-Med programmed freezer (Model 701; Cryo-Med, Mt Clemens, MI) or an alternative uncontrolled hydroxy ethylstarchldimethyl sulfoxide m e t h~d . '~ Recently, we confirmed that blood progenitors can be frozen by this uncontrolled procedure without losing their clonogenic viability or engraftment potential.I5 Fractionation and freezing were completed within 4 hours after apheresis bags were transferred to the processing laboratory. Frozen cells were stored in the liquid phase of liquid nitrogen or in an electric freezer (Sanyo Electric CO, Tokyo, Japan) at -135°C. to 2.0 X 105/mL) were incubated in 35-mm Petri dishes in methylcellulose supplemented with 20% fetal bovine serum, 1% deionized and delipidated bovine serum albumin, 5 X m o m of 2-mercaptoethanol, 400 pg/mL of human transferrin, and 2 UlmL of human recombinant erythropoietin (a gift from Sankyo CO, Ltd, Tokyo, Japan) at 37°C in a humidified atmosphere of 5% carbon dioxide, 5% oxygen, and 90% nitrogen. Triplicate cultures were incubated and CFU-GM was scored on days 13 to 15. As a source of CSFs, we routinely use both 10% phytohemagglutinin-stimulated, leukocyteconditioned medium and a combination of recombinant human factors including 20 ng/mL G-CSF (1 X IO* U/mg: Kirin Brewery CO), 20 ng/mL interleukin-3 (1 X 10' U/mg: Kirin), and 1,000 U/mL interferon-y (5.36 X lo6 U/mg; Nippon Roche, Tokyo, Japan)."j." For standardization, the present study exclusively used data obtained with this combination of recombinant cytokines. In some early patients, unused frozen samples were thawed and reanalyzed. Because of the small number circulating in peripheral blood, CFU-mix was not evaluated.
Calculation of the minimum volume of blood required for processing. In our institute, the number of blood CFU-GM required for successful and rapid engraftment in children with cancer is 10 to 30 X IO4/kg.'O Assuming that no major change develops in the level of blood progenitors during the apheresis procedure, the minimum volume of blood required to process (A), or the minimum number of aphereses required to collect (B), 10 X lo4 CFU-GMkg was calculated for comparative analysis. When more than 10 X lo4 CFU-GMkg was collected in the initial apheresis (B = l), the following formula was used: A (mL/kg) = (volume of blood [mL/ kg] processed X 105)/n0. of CFU-GM/kg collected. When multiple collections were performed (B = Bp), A was calculated as follows: Statistical analysis. To make the analysis of collection data meaningful, collection efficiency was evaluated exclusively using data obtained in aphereses that were performed in the first attempted course of mobilization. Statistical significance was evaluated either by the Cochran-Cox test or Student's t-test, as applicable, using an NEC PC (Nippon Electric CO, Tokyo, Japan) and commercially available computer software (1 -2-3 Medical Statistical Programs, Nankodo, Tokyo). The former method was applied when there was a difference in dispersion. Otherwise, the latter method was used.
A level of P < .OS was considered significant. The correlation between the number of progenitors infused and the days required until recovery of hematopoiesis after PBSCT was evaluated using Pearson's correlation coefficient.
RESULTS
Collection of progenitor cells. A total of 81 aphereses were performed: 79 in the recovery phase of the initial course of mobilization chemotherapy and 2 after mobilization with G-CSF alone. Data on cell yields are presented in Table 1 . Generally, morbidity related to PBSC harvest was low. All arterial punctures were performed in patients with rapidly increasing platelet counts (>l50 X 109/L). Minor and insignificant hematoma formation at the puncture site has been the sole complication directly related to this procedure. Transient and reversible cyanosis or hypotensive episodes developed at the very beginning of apheresis in 2 children. A temporary reduction in the rate of blood withdrawal and the infusion of fluid through the intravenous site induced a prompt recovery in both cases. One patient had an allergic reaction to the red blood cells used in the priming procedure but recovered rapidly without additional therapy. None of the patients developed postapheresis fever. After apheresis, profound thrombocytopenia occurred in all cases and required reinfusion of the platelet-rich plasma collected during stem cell apheresis. Cytopenia lasting for more than 1 week after apheresis, which developed in 1 patient (case no. 17) and required emergent PBSCT, was the most serious complication, as previously reported." Otherwise, none of the patients was readmitted for neutropenia with or without infectious complications. All of the remaining patients received the subsequent course of consolidation chemotherapy without sequelae.
There was a wide variation in the timing of the harvests. The median number of days from the last day of chemotherapy to the day of the initial apheresis was 18.5 (range, 14 to 28). The size of the arterial catheter used was as follows: 24 guage in 4, 22 guage in 29, and 20 guage in 5 children. The mean number of aphereses per patient was 2.1 t 1.0 (range, l to 4). The average rate of blood withdrawal per apheresis ranged from 17 to 46 mL/min (median, 30 mL/ min), depending mainly on the compliance of blood access and tolerability. The volume of blood per kilogram of the patient's body weight processed per apheresis ranged from 85 to 615 mL (median, 270 mL). All apheresis procedures were completed within 3 hours. The median number of cells collected per apheresis was 2.7 X IOR/kg (range, 0.5 to 28 X 108/kg) for MNC and 34 X 104/kg (2 to 1,530 X 104/kg) for CFU-GM. CD34 surface antigen was evaluated in 46 samples and the median yield was 15 X lO%g (range, 2 to 107 X 106/kg). Most patients underwent multiple courses of apheresis to secure engraftment or for repetitive transplants. The total number of cells collected per patient was 6.1 X 10%g (range, 1.6 to 34.8 X 108/kg) for MNC, 126 X IO4/ kg (range, 12 to 1,530 X 104/kg) for CFU-GM, and 31 X 106/kg (range, 5 to 107 X 106/kg) for CD34' cells. In 21 of the 81 aphereses, PBSC were mobilized by G-CSF. There was no statistically significant difference between the numbers of CFU-GM and CD34+ cells collected per apheresis without G-CSF (31 X 104/kg; range, 2 to 302 X 104/kg; n = 60; and 15 X 106/kg; range, 2 to 64 X 106/kg; n = 29; respectively) and those with G-CSF (53 X 104/kg; range, 6 to 1,530 X 104/kg; n = 21; and 15 X lO6/kg; range, 2 to 107 X 106kg; n = 17; respectively). There were significant correlations ( P < .01) between the collected numbers of MNC versus CFU-GM (I = .534), MNC versus CD34' cells (I = .489), and CFU-GM versus CD34' cells (Y = ,948). On the other hand, no relationship was found between the volume of blood processed and Cm-GM or CD34' cells.
There was a wide range (2 to 521 mL/kg) in the calculated minimum volume of blood that had to be processed to collect 10 X IO4 CFU-Gh4kg. The median value was 37 mWkg. No difference was found in the values between patients with liquid (leukemias or NHL) versus solid tumors (Fig I) . Thirty-three patients (87%) required only a single apheresis to collect the minimum requirement of 10 X IO4 CFU-GM/ kg, 2 required a second apheresis, and the remaining 3 required a third. When 30 x IO4 CFU-GMkg was used as a minimum requirement, 28 patients (74%) met this criterion with a single apheresis.
Hematopoietic engraftment kinetics after PBSCT. TOXicities observed with the infusion of thawed graft are summarized in Table 2 . Compared with their older counterparts, smaller children appeared to tolerate infusion toxicities relatively well.20 The transplant and engraftment results are summarized in Table 3 . The number of infused MNC, CFU-GM, and CD34' cells per kilogram of the patient's body weight were, respectively, 3.9 x 10' (range, 1 to 15 X 10% 62 x IO4 (range, 13 to 288 X lo4), and 25 X 10' (range, 8 to 95
x lo6). These cells were collected by l to 4 aphereses (2.3 -+ 1). There was a significant correlation ( P < .O1) between the number of infused CFU-GM and CD34' cells (I = ,7821, whereas no correlation was found between MNC and CFU-GM or CD34' cells. After PBSCT, 3 patients received G-CSF to enhance hematopoietic recovery. The speed of hema- topoietic recovery was evaluated in terms of the median number of days required to achieve an AGC of 0.5 X lo9/ L, a white blood cell count (WBC) of 1.0 X lo9& and a platelet count of 50 X 1 0 9 L These values were, respectively, 10 days (range, 6 to 15 days), 10 days (range, 6 to 15 days), and 14 days (range, 9 to 46 days). Patients remained dependent on transfusion support with red blood cells and platelets for a median of 8 days (range, 0 to 35 days) and 10 days (range, 5 to 35 days), respectively. There was a significant correlation (P < .01) between the number of CFU-GM infused per kilogram of the patient's body weight and the time to achieve an AGC of greater than 0.5 X 109/L ( r = -.693; Fig 2) or a WBC count of greater than 1 X 109L (r = .638). However, no significant correlation was observed with platelet recovery. The number of infused MNC or CD34' cells had no significant effect on engraftment.
DISCUSSION
Potential problems related to apheresis in small children include access to blood and tolerance of extracorporeal circulation. The retrospective nature of this study limits the value of our results. There are still many valid questions concerning PBSC collection in small children that remain unanswered, and the optimization of mobilization has not been 377 fully tested. However, the present data can serve as comparative historical experience for future assessment of the efficacy and safety of this procedure. The data suggest that, with certain adjustments, the procedure is simple and effective even in very small children with active malignancy. Complications caused by fluid shift that may occur at the very beginning of apheresis9.'' could be overcome by additional priming with blood and by using a relatively low initial rate of withdrawal. Outside of our team, thus far only Demeocq et a14 have provided a comprehensive report with a large number of patients concerning the collection of PBSC in very small children. They collected PBSC by apheresis using a Cobe Spectra from 20 children weighing less than 25 kg with a median age of 4 years. In that report, a central catheter was inserted to withdraw blood and a peripheral vein was used for return, which is the procedure applied in most centers for pediatric patients. The median rate of blood withdrawal and the mean number of aphereses per patient in their study were 13.8 mL/min (range, 7 to 22 ml/min) and 3.3 (range, 1 to 4), respectively. The mean total collection time was 8.5 hours. In our experience, use of an arterial catheter has substantially increased the speed of collection.
The rate of blood withdrawal in this study ranged from 17 to 46 mL/min, with a median of 30 mL/min, and a median of 270 mL/kg of blood could be processed within 3 hours. The median number of CFU-GM and CD34' cells collected per apheresis was 34 X 104/kg and 15 X 106/kg, respectively. The total number of cells collected per patient was 126 X 104/kg for CFU-GM and 31 X lO%g for CD34+ cells. Notably, the minimum requirement of 10 X lo4 CFU-GMkg was collected in a single apheresis in 87% of the patients. In the study by Demeocq et a1: mobilization with CSF reportedly had beneficial effects: the median number of CFU-GM per procedure was 20.4 X 104/kg with CSF mobilization but only 2.6 X 104/kg without CSF. In a previous study, we reported that G-CSF is valuable in mobilizing PBSC in heavily treated patients." However, when apheresis is performed Nineteen patients received the cytoreductive MCVAC regimen before PBSCT, and the remaining four patients (cases no. 10, 11, 22, and 36)
were treated with regimens containing high-dose melphalan during the early stage of therapy for pediatric cancer, it is population. Most other centers prefer to use a central line unlikely that the use of G-CSF can further expand the numfor withdrawing blood and, very often, for returning blood. ber of PBSC above that which can be achieved by chemoAt the initial presentation of children with malignant disease, therapy alone." In the current study, we again failed to obwe, like other centers, routinely insert a central line into serve any data that would confirm the benefit of G-CSF. The patients for supportive therapy. A line with a rather large higher efficiency of our procedure may discount the value lumen needs to be inserted for later apheresis. After collecof CSF mobilization in a selected patient population. Thus, tion is complete, these lines continue to be used throughout the advantages of our procedure are reduced collection time, the remainder of chemotherapy until they are removed after fewer aphereses, and, thus, less of a burden for the transplant PBSCT. This clearly increases the difficulty and complexity team and the patient. All of these benefits can be achieved of managing small children. Moreover, the technical diffiwithout an increase in clinical risk. It is very unlikely that culty associated with placement of a double-lumen catheter this difference in collection results is caused by the differin small children under general anesthesia is obvious. ence in the type of apheresis machine (CS-3000 v Cobe A long central line usually offers too much resistance to Spectra), because the two machines give a comparable perallow rapid blood flow (at a rate 30 to 40 mllmin), which formance." Thus, the use of an arterial catheter appears to could be easily obtained in many of our patients. We frecontribute to the superior results obtained here. Although we did not apply the SVCC procedure in this study, a currently ongoing study indicates that this procedure is also effective in small children (unpublished data).
Maintaining an adequate rate of blood flow during apheresis is crucial to making the procedure efficient and successful. We use an arterial catheter that is inserted for only a short period of time, because collection of PBSC can be accomplished in three aphereses in most patients. Although our experience does not support the argument that this procedure increases the complexity of the procedure or the risk to the ~a t i e n t ,~ this issue should be examined in a larger quently observe the formation of clots of various sizes in the catheter, particularly when G-CSF mobilization is applied. In these situations, direct infusion of these clots into the cardiopulmonary system increases the risk of catheter-related infection and jeopardizes the valid line. Based on these considerations, we use an arterial catheter in our collection protocol. Placement of an arterial catheter is a routine procedure in neonatology and pediatric cardiology. At the University of Tokushima, we have thus far performed 39 1 aphereses in 83 children, and no complication either directly or indirectly related to the use of the arterial catheter has been observed (unpublished data). Furthermore, we do not use collected for infusion. However, this must be weighed against the labor and cost related to the apheresis procedure and the added stress on the patient.
We conclude that collection of PBSC is a safe and practical procedure, even in very small children. Collected cells can be cryopreserved without losing their engraftment potential. The clinical benefit of PBSCT in this patient population has not been fully tested. However, we predict that its role outside of cancer therapy will continue to evolve. Because collection of PBSC appears to be realistic and less traumatic than marrow harvest, it should play a major role in gene therapy, in which many of the target patients are infants or small children. fresh-frozen plasma or albumin during extracorporeal circulation, which eliminates a potential risk to the patient.
The quality and quantity of the collected cells were proven in the subsequent transplant. In this study, the median number of days required to achieve an AGC of 0.5 X 109/L and a platelet count of 50 X 109/L after PBSCT were, respectively, 10 and 14. The patients remained dependent on platelet transfusion support for 10 days. Thus, the results are far superior to those reported after autologous bone marrow transplantation." This is likely because the PBSC collected by apheresis contain more mature progenitors than marrow graft.'3 The consequent infusion of a larger number of stem cells leads to the characteristic rapid hematopoietic engraftment after PBSCT. The results with CFU-GM and CD34 assays of progenitors appear to correlate In many centers, these assays have been used as an indication of an expected successful engraftment. In this study with a limited number of patients, we observed a significant correlation between the time to leukocyte engraftment and the number of CFU-GM infused, but not with the number of MNC or CD34+ cells. This finding may be due to differences in hematopoiesis between adults and small children. In a previous study, we suggested that children may possess a larger proliferative capacity in hematopoiesis than adult patients and that more P B X could be collected from smaller children than from older children.' Future studies should help clarify our adult versus pediatric transplant experience. To enhance recovery speed, as many CFU-GM as possible should be
